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Abstract
Background:
Pulmonary arterial hypertension (PAH) is a devastating disease characterized by elevated pulmonary
pressures that lead to right heart failure and premature mortality. Patients experience multiple symptoms
including dyspnea, fatigue and chest pain, but little is known about sleep disturbance, PAH symptoms,
psychological distress and health-related quality of life (HRQOL) in PAH.
Aim:
The purpose of this study was to describe the occurrence of sleep disturbance and compare PAH symptoms,
psychological distress, and HRQOL across severity of sleep disturbance.
Methods:
One hundred and ninety-one participants completed a socio-demographic and clinical data form, PAH
Symptom Severity Scale, Profile of Mood States (POMS) short form and the Medical Outcomes Short
Form-36 (SF-36). Descriptive statistics were used to describe sleep disturbances; analysis of variance models
were used to quantify differences in PAH symptoms, psychological distress and HRQOL by sleep disturbance
groups.
Results:
The majority of participants (n=162, 85%) were women with a mean age of 53 years. Sixty-five (34%)
reported no sleep disturbance; 54 (28%) mild sleep disturbance; 41 (22%) moderate sleep disturbance; and
31 (16%) severe sleep disturbance. Those reporting higher sleep disturbance severity reported worse PAH
symptoms, psychological distress, and HRQOL.
Conclusions:
Sleep disturbance is a significant finding in PAH. Increasing levels of sleep disturbance are associated with
worse PAH symptoms, psychological states, and health-related quality of life. Interventions that decrease sleep
disturbances may improve symptoms and HRQOL.
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Abstract 
Background: Pulmonary arterial hypertension (PAH) is a devastating disease characterized by 
elevated pulmonary pressures that lead to right heart failure and premature mortality. Patients 
experience multiple symptoms including dyspnea, fatigue and chest pain, but little is known 
about sleep disturbance, PAH symptoms, psychological distress and health-related quality of life 
(HRQOL) in PAH. 
Aim: To describe the occurrence of sleep disturbance and compare PAH symptoms, 
psychological distress and HRQOL across severity of sleep disturbance. 
Methods:  One-hundred ninety one participants completed a socio-demographic and clinical data 
form, PAH Symptom Severity Scale, Profile of Mood States short form (POMS) and the Medical 
Outcomes Short From-36 (SF-36). Descriptive statistics were used to describe sleep 
disturbances; analysis of variance models were used to quantify differences in PAH symptoms, 
psychological distress and HRQOL by sleep disturbance groups. 
Results: The majority of participants (n=162, 85%) were women with a mean age of 53 years. 
Sixty-five (34%) reported no sleep disturbance; 54 (28%) mild sleep disturbance; 41 (22%) 
moderate sleep disturbance; and 31 (16%) severe sleep disturbance. Those with reporting higher 
sleep disturbance severity reported worse PAH symptoms, psychological distress and health-
related quality of life.  
Conclusions: Sleep disturbance is a significant finding in PAH. Increasing levels of sleep 
disturbance are associated with worse PAH symptoms, psychological states, and health-related 
quality of life. Interventions that decrease sleep disturbances may improve symptoms and 
HRQOL. 
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Introduction  
 Pulmonary arterial hypertension (PAH), one type of pulmonary hypertension, is a 
devastating illness affecting primarily young to middle-aged women. PAH is defined 
hemodynamically as a mean pulmonary arterial pressure > 25 mmHg and a pulmonary capillary 
wedge pressure < 15 mmHg.(1) Overtime, these elevated pulmonary pressures lead to right heart 
failure. The etiology of PAH includes idiopathic, familial, connective tissue disease, 
portopulmonary hypertension, sickle cell disease and congenital heart disease. Approximately 
80% of those diagnosed with PAH are women. The mean age at diagnosis is 50 years,(2) 
although there is typically a delay of 2 years from symptom onset to diagnosis.(3) Estimated 
prevalence of PAH is 7.6 to 15 cases per million.(4, 5) Symptoms of PAH include fatigue and 
dyspnea on exertion that may be attributed to other cardiopulmonary disorders. Mortality 
remains high; 61% at 5 years.(6, 7)  
 Recent studies show patients with PAH experience multiple symptoms that interfere with 
their lives and negatively affect their quality of life.(7-9) Sleep disturbance is increasingly 
recognized as a factor interfering with the ability to cope with symptoms and maintain health-
related quality of life (HRQOL).(10)  Only two studies investigating sleep disturbance in 
pulmonary hypertension have been conducted and these studies illustrate that sleep disturbances 
may be a factor greatly interfering with the HRQOL of these patients.(10, 11)  Sleep disturbance 
in PAH can be caused by insomnia and restless leg syndrome. Seventy-three percent of patients 
(N=40) with pulmonary hypertension had poor sleep quality that was associated with depression, 
dyspnea and decreased HRQOL.(10) Fifty percent had insomnia, 26% reported excessive 
daytime sleepiness (EDS) and 30% were found to have restless leg syndrome. Prostanoid therapy 
was associated with improved HRQOL but not sleep quality.(10) In another study 46% (N=55) 
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of those with pulmonary hypertension had restless leg syndrome.(11) Those with a history of 
hypothyroidism and opioid use for leg pain were most likely to have restless leg syndrome. 
Limitations of these studies included small sample sizes and inclusion of various etiologies of 
pulmonary hypertension, making it difficult to generalize to those with PAH only.  
  These preliminary studies suggest sleep disturbance is present in pulmonary 
hypertension, but the prevalence of sleep disturbance in those with PAH only remains unknown. 
Understanding the effects of sleep disturbance in patients with PAH may have implications for 
interventions and patient outcomes such as morbidity, psychological distress and HRQOL. The 
aims of this study were to:  
(1) describe the occurrence of sleep disturbance and 
(2) compare PAH symptom, psychological distress and HRQOL across severity of 
sleep disturbance. 
Methods 
Study Design 
 A cross-sectional study design was used. 
Sample 
 The convenience sample included 191 participants recruited from United States PAH 
support groups, an on-line Pulmonary Hypertension Association (PHA) discussion board, and at 
Northeast United States and international Pulmonary Hypertension conferences. The PHA 
sponsors a biennial conference where investigators can recruit and enroll study participants.  At a 
monthly support meeting the principal investigator (PI) was introduced and allowed to briefly 
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discuss the purpose of this study and invite participants to approach the PI after the meeting if 
they wished to participate. An advertisement was posted by the PHA website administrator; 
participants contacted the PI via email if they were interested in participating. Only those 
patients self-reporting PAH who were able to read and speak English were included. Patients 
were enrolled over an 18 month period.  
Measures 
 Participants completed the following questionnaires:  a socio-demographic and clinical 
data form, the PAH Symptom Severity Scale, the Profile of Mood States (POMS) short form the 
Medical Outcomes Study Short Form- 36 (SF-36).  
Socio-demographic and Clinical Data Form:  Socio-demographic and clinical variables were 
collected via a tool developed by the research team. Socio-demographic information included 
gender, age, ethnicity, education, occupation and employment status. Self-reported clinical 
variables included date of PAH diagnosis, PAH etiology, initial symptoms of PAH, oxygen and 
medication use. World Health Organization (WHO) functional class(1) was assigned by the PI 
(LAM) using assessment data from self-reported symptoms. WHO functional class I includes 
those with PAH who do not have symptoms such as shortness of breath (SOB) with exertion. 
Those with WHO functional class II have mild SOB with exertion while WHO functional class 
III patients have moderate to severe symptoms of SOB with exertion. WHO functional class IV 
patients have symptoms at rest.(12) 
Sleep Disturbance: Sleep disturbance was measured by a single item on the PAH Symptom 
Severity Scale labeled “sleep difficulty”.  Sleep difficulty is measured on a 0 to 10 scale with 
zero indicating absence of sleep difficulty and 10 representing the worst possible sleep difficulty. 
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PAH Symptom Severity Scale:  The PAH Symptom Severity Scale is a symptom scale developed 
by the research team that contains 17 symptoms: SOB with exertion, SOB lying down, SOB at 
rest, awakening at night SOB, fatigue, sleep disturbance, chest pain, abdominal swelling, 
swelling of ankles and feet, syncope, palpitations, dizziness, cough, nausea, loss of appetite, 
hoarseness, Raynaud’s phenomenon (cold, numbness of extremities). Symptoms were selected 
based on the literature,(13-15) input from the research team, experts caring for patients with 
PAH and patients with PAH. Symptoms are rated on a 0-10 scale, with zero indicating an 
absence of the symptom and 10 indicating “extremely intense”. Participants are asked to rate 
their symptoms over the past month. The Cronbach alpha for the scale is typically .90-.91;(7) in 
the current study alpha was .90. Validity testing is on-going. 
Psychological states The POMS short form comprised 30 items that measure fluctuating mood 
states. These items form six subscales anger, anxiety, depression, confusion, fatigue and vigor. 
Each item is rated on a 5 point Likert scale, 0 (not at all) to 4 (extremely) for each mood state. 
Higher scores indicate more negative moods, except vigor which is reversed scored. Concurrent 
validity was established using the modified Hopkins Symptom Distress Scales and Minnesota 
Multiphasic Personality Inventory-2.(16) Internal consistency ranges from 0.84 to 0.95.(16, 17) 
The Cronbach alpha for the current study was .70. 
SF-36 The SF-36 is a widely used instrument that measures generic HRQOL. The SF-36 
measures physical and mental health by assessing eight subscales. The subscales (general health, 
physical functioning, role physical, pain, fatigue, social functioning, mental health, role 
emotional) and each composite summary score (mental and physical) are reported on a scale of 
0-100 with higher scores indicating better HRQOL. Validity (18) and reliability have been 
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established with Cronbach alpha ranges between .73-.96.(19) The Cronbach alpha for the current 
study was .84. 
Procedure 
 This investigation conformed with the principles outlined in the Declaration of 
Helsinki.(20) This study was approved by the hospital and University Institutional Review 
Boards. Participants were given paper and pencil forms and questionnaires to complete along 
with a self-addressed stamped envelope. Participants were given unique identification numbers. 
Return of completed surveys was considered consent to participate. 
Statistical Analysis 
 The primary outcome measure of sleep disturbance was assessed using the PAH 
Symptom Severity Scale. Participants were categorized into four groups on the basis of self-
reported sleep disturbance: no (0) mild (1-3), moderate (4-7), and severe (8-10).  These 
categories were established using existing literature and investigator input.(21-23) Descriptive 
statistics are used to characterize the population to which inferences may be made.  Specifically, 
means and standard deviations are provided for continuous socio-demographic and clinical 
characteristics overall, and by sleep disturbance groups, while frequencies and percents are 
provided for categorical variables. Comparisons of continuous and categorical socio-
demographic and clinical characteristics across groups are made using one-way Analysis of 
Variance (ANOVA) models and chi-square statistics, respectively. Medications are compared 
across groups using indicator variables for each specific medication. The total number of PAH 
symptoms among the sixteen symptoms examined is compared across sleep disturbance groups 
using a one-way ANOVA model and the F statistic, with post-hoc pair-wise comparisons 
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accomplished on the basis of Dunnett's tests.  Similarly, PAH symptom intensity, as well as 
POMS and SF-36 subscales, are described overall and within sleep disturbance groups using 
means and standard deviations, and compared using one-way ANOVA models and Dunnett's 
pair-wise post-hoc tests.  No adjustment was made for multiplicity. All statistical analyses were 
accomplished using SPSS version 20.(24)  Statistical significance was taken at the 0.05 level. 
  
Results 
 Of the 191 participants, 126 (66%) reported some level of sleep disturbance, Table 1. For 
the sleep disturbance categories, 65 (34%) had  no sleep disturbance, 54 (28%) mild, 41 (22%) 
moderate, and 31 (16%) severe sleep disturbance. There were significant differences among the 
sleep disturbance groups with regards to PAH symptoms, psychological distress and HRQOL.  
 Table 2 provides estimates (mean + SD) for symptom intensity for 16 PAH symptoms. 
The symptoms with the highest mean scores for the total sample were SOB with exertion and 
fatigue.  All symptoms differed significantly between the no sleep disturbance and the severe 
sleep disturbance groups. Syncope did not differ among the groups. Pair-wise post-hoc 
differences are also indicated in Table 2.  Figure 1 provides a visual display of the distribution 
for the total number of symptoms by each sleep disturbance group.  
 With regards to psychological distress, the sleep disturbance groups differed significantly 
on all the POMS subscales (anxiety, depression, anger, vigor, fatigue, confusion) and total score, 
with results for pair-wise post-hoc differences displayed in Table 3. Confusion was the only 
psychological state that differed between no and moderate sleep disturbance.  
 Similarly, the sleep disturbance groups differed significantly on all SF-36 subscales and 
composite summary scores (Table 4). The role emotional subscale differed only between the no 
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disturbance and mild sleep disturbance and the no disturbance and severe sleep disturbance 
groups.  
Discussion 
 This study demonstrates that sleep disturbance is common in PAH and associated with 
other PAH symptoms, psychological distress and HRQOL.  As sleep disturbance severity 
increases, so does the occurrence of PAH symptoms and there is greater PAH symptom severity. 
The linear increase in symptom distress in relation to increasing sleep disturbance suggests that 
sleep disturbance increases with symptom severity, creating an escalating cycle of sleep 
disturbance and symptoms severity. Higher WHO functional classes and increased oxygen use 
were more common as sleep disturbance severity increased.  
 In our study those with worse sleep disturbance had higher PAH symptom severity and 
psychological distress. This is consistent with the results from a small study of  patients with 
pulmonary hypertension  where sleep quality was associated with symptoms (breathlessness, 
mood and energy), depression and dyspnea.(10) In patients with heart failure (HF), depression 
and fatigue have been associated with insomnia.(25) Additionally our study expands current 
knowledge of PAH symptom severity by the use of a comprehensive  symptom profile. These are 
new findings that may provide a direction for future intervention. Perhaps screening and treating 
symptoms in PAH may improve sleep, but more research is necessary to test this hypothesis. 
 Psychological distress may be another factor explaining the occurrence of sleep 
disturbance. Our study shows that sleep disturbance severity was associated with anger, anxiety, 
depression, confusion and fatigue. Other studies have shown that depression is associated with 
sleep disturbance in PAH(10) and depression and anxiety have been found to be prevalent in 
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patients with PAH.(14, 15, 26)  While we do not know if sleep disturbance is the outcome of 
patients experiencing exacerbated symptoms and psychological distress, these findings provide 
us with possible directions for further investigation. For example, future research could target 
optimal symptom control (e.g. SOB), which could improve sleep. Conversely, improving sleep 
in the patient with PAH may improve their other symptoms.  
 Our study showed an association with PAH symptom severity and HRQOL. Similar to 
our findings, sleep disturbance is common in HF and impairs HRQOL.(27, 28)  Impaired sleep 
and EDS affect cognition, physical functioning and treatment adherence in patients with HF.(25, 
29-32) Our study showed those with worse self-reported sleep disturbance had poorer physical 
functioning. Insomnia symptoms are also associated with increased depression, fatigue, EDS and 
functional performance in HF (25) and affects global perceived health in sleep-disordered 
breathing.(33)  Self-reported sleep quality is also associated with functional performance and 
mental health in HF.(34)  We found those with PAH who had sleep disturbances reported higher 
levels of fatigue and depression. 
 Those with worse sleep also had lower HRQOL in our study. Physically, those with sleep 
disturbance also experienced fatigue and limitations in performing physical activities. 
Psychologically, those with sleep disturbance had psychological distress, social disability and 
emotional problems. A study of patients with pulmonary hypertension found sleep disturbance 
was associated with activity and HRQOL.(10) Those with sleep disturbance had worse physical 
functioning and lower mental health HRQOL. Studies have shown that insomnia (25) and sleep 
quality (35) are associated with functional performance in HF. More investigation is needed to 
determine possible underlying mechanisms of sleep disturbance than influence HRQOL in PAH. 
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 Sixty percent of our sample reported oxygen use and those patients tended to also have 
more sleep disturbance than those not reporting oxygen use  Patients with obstructive sleep 
apnea and EDS were also found to have impaired HRQOL(36) and  nocturnal oxygen 
desaturation was associated with HRQOL.  In patients with stable HF nocturnal brain (B-type) 
natriuretic peptide (BNP) changes were related to the severity of night time hypoxemia but not to 
the type of sleep-discorded breathing episodes or arousals. No relationship was found between 
BNP and the frequency of sleep-disordered events. Nocturnal, intermittent hypoxemia in HF was 
associated with the outflow of cardiac natriuretic peptides from cardiac myocytes, suggesting 
that nocturnal hypoxia can increase cardiac wall stress and worsen cardiac function. The severity 
of hypoxemia did not correlate with increased BNP levels. Sleep-disordered breathing in patients 
with HF may have a negative impact due to hypoxia.(37)  Similar to these studies, hypoxemia 
may be a contributor to sleep disturbance in PAH but more investigation is needed. We did not 
collect data on how patients were using their oxygen therapy (continuous, as needed, or at night 
only). There could be an undiagnosed sleep disorder or nocturnal hypoxemia contributing to the 
perception of disturbed sleep in PAH, but more investigation is needed to clarify the relationship 
between oxygen use and sleep disturbance. 
 While our study demonstrates the prevalence of sleep disturbance in patients with PAH is 
common, the reason for this problem remains unclear. Medications such as beta blockers have 
been implicated in sleep problems,(38) but were not associated with sleep disturbance in PAH, 
nor were angiotensin converting enzyme inhibitors (ACEI) or angiotensin receptor agonists 
(ARB) in the current study. This may be due to the relatively few people taking beta blockers, 
ACEI and ARB in this study.  
Limitations  
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 This study has several limitations. First, a non-random sample was used for this study. 
Self-report instruments can lead to recall bias among participants. The sleep measure was only a 
single item measure from the PAH Symptom Severity Scale. Single item measures have been 
shown to be valid and reliable in measuring other concepts such as stress, (39) and quality of 
life.(40)  Sleep quality(41) and sleepiness(42) also have been measured using single items. This 
single item gives a broad but vague description of the type of sleep disturbance in PAH. We also 
did not measure sleep objectively using polysomnography. PAH has several etiologies, some of 
the subgroups have very small sample sizes, so there may be differences in how they experience 
symptoms, psychological distress and HRQOL. The Cronbach alpha of the POMS was 
borderline in this sample suggesting this may not be the best measure of psychological distress in 
PAH. Participants self-reported their PAH status, so we do not have verification of their 
diagnostic hemodynamics to verify the PAH diagnosis. Although PAH primarily affects women, 
men are underrepresented in this sample. Other clinical variables such as current hemodynamics 
were not collected and may play an important role in sleep disturbance.  
Conclusions 
 We have established a link between difficulty sleeping and PAH symptoms, 
psychological distress and HRQOL in PAH. Now a follow up study is necessary to define the 
nature of the sleep disturbance. This study demonstrates the pervasiveness of sleep disturbance 
and the interplay among symptoms, psychological distress and HRQOL in patients with PAH. 
As we continue to describe the symptom experience in PAH, the need for comprehensive 
symptom assessment is needed in the clinical setting. Assessment of symptoms and sleep 
disturbance in PAH and implementation of interventions could improve outcomes important to 
patients such as symptom control, functional status and HRQOL. In addition, improvement in 
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sleep and other symptoms may have an impact on hospital readmissions, morbidity and mortality 
outcomes but further research is needed to explore these issues.  
       In summary, we have demonstrated that those patients with PAH have sleep disturbance and 
those with increased sleep disturbance have worse PAH symptoms, psychological distress and 
HRQOL. Future research will need to further define sleep disturbance and underlying 
mechanisms along with designing and testing interventions to target sleep and symptoms. 
Working to improve sleep and symptoms may have an important impact on HRQOL.  
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Implications for Practice 
 Sleep disturbance is common in pulmonary arterial hypertension (PAH). 
 Those with increasing difficulty sleeping have worse PAH symptoms and health-related 
quality of life. 
 Screening for sleep difficulty in PAH is needed and interventions to improve sleep need 
to be developed and tested. 
 
Acknowledgements 
We would like to thank those who participated in this study. 
Declaration of Conflicting Interests 
 The Authors declare that there is no conflict of interest. 
Funding Acknowledgements 
This work was partially supported by a Bouve College of Health Sciences, Northeastern 
University intramural grant and Sigma Theta Tau International Gamma Epsilon grant and the 
Biobehavioral Research Center, University of Pennsylvania School of Nursing. 
 
 
 
 
 
 
 
17 
 
 
 
References 
1. Galiè N, Hoeper MM, Humbert M, Torbicki A, Vachiery J-L, Barbera JA, et al. 
Guidelines for the diagnosis and treatment of pulmonary hypertension. European Heart Journal. 
2009;30(20):2493-537. 
2. Badesch DB, Raskob GE, Elliott CG, Krichman AM, Farber HW, Frost AE, et al. 
Pulmonary Arterial Hypertension: Baseline Characteristics From the REVEAL Registry. Chest. 
2010;137(2):376-87. 
3. Brown LM, Chen H, Halpern S, Taichman D, McGoon MD, Farber HW, et al. Delay in 
Recognition of Pulmonary Arterial Hypertension. Chest. 2011;140(1):19-26. 
4. Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, et al. Pulmonary 
Arterial Hypertension in France: Results from a National Registry. Am J Respir Crit Care Med. 
2006;173(9):1023-30. 
5. Butrous G, Ghofrani HA, Grimminger F. Pulmonary Vascular Disease in the Developing 
World. Circulation. 2008;118(17):1758-66. 
6. Thenappan T, Shah SJ, Rich S, Tian L, Archer SL, Gomberg-Maitland M. Survival in 
pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation. European 
Respiratory Journal. 2010;35(5):1079-87. 
7. Matura L, McDonough A, Carroll D. Cluster analysis of symptoms in pulmonary arterial 
hypertension: a pilot study. European Journal of Cardiovascular Nursing. 2012;11(1):51-61. 
18 
 
8. Matura L, McDonough A, Carroll D. Predictors of Health-Related Quality of Life in 
Patients With Idiopathic Pulmonary Arterial Hypertension. Journal of Hospice & Palliative 
Nursing. 2012;14(4):283-92 10.1097/NJH.0b013e3182496c04. 
9. McDonough A, Matura L, Carroll D. Symptom Experience of Pulmonary Arterial 
Hypertension Patients. Clinical Nursing Research. 2011;20(2):120-34. 
10. Batal O, Khatib O, Bair N, Aboussouan L, Minai O. Sleep Quality, Depression, and 
Quality of Life in Patients with Pulmonary Hypertension. Lung. 2011;189(2):141-9. 
11. Minai OA, Malik N, Foldvary N, Bair N, Golish JA. Prevalence and Characteristics of 
Restless Legs Syndrome in Patients With Pulmonary Hypertension. The Journal of Heart and 
Lung Transplantation. 2008;27(3):335-40. 
12. Barst RJ, McGoon M, Torbicki A, Sitbon O, Krowka MJ, Olschewski H, et al. Diagnosis 
and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol. 
2004;43(12_Suppl_S):40S-7. 
13. Flattery MP, Pinson JM, Savage L, Salyer J. Living with pulmonary artery hypertension: 
Patients’ experiences. Heart & Lung: The Journal of Acute and Critical Care. 2005;34(2):99-107. 
14. White J, Hopkins R, Glissmeyer E, Kitterman N, Elliott CG. Cognitive, emotional, and 
quality of life outcomes in patients with pulmonary arterial hypertension. Respiratory Research. 
2006;7(1):55. 
15. Lowe B, Grafe K, Ufer C, Kroenke K, Grunig E, Herzog W, et al. Anxiety and 
Depression in Patients With Pulmonary Hypertension. Psychosom Med. 2004;66(6):831-6. 
16. McNair DM, Lorr M, Droppleman LF, McNair DM, Lorr M, Droppleman LF. Profile of 
Mood States--Brief. North Tonawanda, NY: MHS/Multi-Health Systems; 2009. 
19 
 
17. Lutgendorf SK, Garand L, Buckwalter KC, Reimer TT, Hong S-Y, Lubaroff DM. Life 
Stress, Mood Disturbance, and Elevated Interleukin-6 in Healthy Older Women. The Journals of 
Gerontology Series A: Biological Sciences and Medical Sciences. 1999;54(9):M434-M9. 
18. McHorney CA, Ware JE, Jr., Raczek AE. The MOS 36-Item Short-Form Health Survey 
(SF-36): II. Psychometric and Clinical Tests of Validity in Measuring Physical and Mental 
Health Constructs. Medical Care. 1993;31(3):247-63. 
19. Brazier JE, Harper R, Jones NM, O'Cathain A, Thomas KJ, Usherwood T, et al. 
Validating the SF-36 health survey questionnaire: new outcome measure for primary care. 
British Medical Journal. 1992;305(6846):160-4. 
20. Rickham P. Human experimentation. Code of Ethics of the World Medical Association. 
Declaration of Helsinki. British Medical Journal. 1964;2(5402):177. 
21. Chow E, Doyle M, Li K, Bradley N, Harris K, Hruby G, et al. Mild, moderate, or severe 
pain categorized by patients with cancer with bone metastases. Journal of palliative medicine. 
2006;9(4):850-4. 
22. Serlin RC, Mendoza TR, Nakamura Y, Edwards KR, Cleeland CS. When is cancer pain 
mild, moderate or severe? Grading pain severity by its interference with function. Pain. 
1995;61(2):277-84. 
23. Given B, Given CW, Sikorskii A, Jeon S, McCorkle R, Champion V, et al. Establishing 
Mild, Moderate, and Severe Scores for Cancer-Related Symptoms: How Consistent and 
Clinically Meaningful Are Interference-Based Severity Cut-Points? Journal of Pain and 
Symptom Management. 2008;35(2):126-35. 
24. IBM. Statistical Package for the Social Sciences (SPSS) Armonk, NY: IBM, Inc.; 2012. 
20 
 
25. Redeker NS, Sangchoon J, Muench U, Campbell D, Walsleben J, Rapoport DM. 
Insomnia symptoms and daytime function in stable heart failure. Sleep. 2010;33(9):1210-6. 
26. McCollister DH, Beutz M, McLaughlin V, Rumsfeld J, Masoudi FA, Tripputi M, et al. 
Depressive Symptoms in Pulmonary Arterial Hypertension: Prevalence and Association With 
Functional Status. Psychosomatics. 2010;51(4):339-3398. 
27. Chen H-M, Clark AP. Sleep disturbances in people living with heart failure. Journal of 
Cardiovascular Nursing. 2007;22(3):177-85. 
28. Liu J-C, Hung H-L, Shyu Y-K, Tsai P-S. The impact of sleep quality and daytime 
sleepiness on global quality of life in community-dwelling patients with heart failure. Journal of 
Cardiovascular Nursing. 2011;26(2):99-105. 
29. Riegel B, Moelter ST, Ratcliffe SJ, Pressler SJ, De Geest S, Potashnik S, et al. Excessive 
Daytime Sleepiness is Associated With Poor Medication Adherence in Adults With Heart 
Failure. Journal of Cardiac Failure. 2011;17(4):340-8. 
30. Riegel B, Weaver TE. Poor sleep and impaired self-care: Towards a comprehensive 
model linking sleep, cognition, and heart failure outcomes. European Journal of Cardiovascular 
Nursing. 2009;8(5):337-44. 
31. Redeker NS. Sleep Disturbance in People With Heart Failure: Implications for Self-care. 
Journal of Cardiovascular Nursing. 2008;23(3):231-8 10.1097/01.JCN.0000305094.20012.76. 
32. Redeker NS, Muench U, Zucker MJ, Walsleben J, Gilbert M, Freudenberger R, et al. 
Sleep disordered breathing, daytime symptoms, and functional performance in stable heart 
failure. Sleep. 2010;33(4):551-60. 
21 
 
33. Broström A, Strömberg A, Dahlström U, Fridlund B. Sleep difficulties, daytime 
sleepiness, and health-related quality of life in patients with chronic heart failure. Journal of 
Cardiovascular Nursing. 2004;19(4):234-42. 
34. Johansson P, Alehagen U, Svensson E, Svanborg E, Dahlström U, Broström A. 
Determinants of global perceived health in community-dwelling elderly screened for heart 
failure and sleep-disordered breathing. Journal of Cardiovascular Nursing. 2010;25(5):E16-E26. 
35. Redeker NS, Hilkert R. Sleep and Quality of Life in Stable Heart Failure. Journal of 
Cardiac Failure. 2005;11(9):700-4. 
36. Martínez-García MA, Soler-Cataluña JJ, Román-Sánchez P, González V, Amorós C, 
Montserrat JM. Obstructive sleep apnea has little impact on quality of life in the elderly. Sleep 
Medicine. 2009;10(1):104-11. 
37. Gottlieb JD, Schwartz AR, Marshall J, Ouyang P, Kern L, Shetty V, et al. Hypoxia, Not 
the Frequency of Sleep Apnea, Induces Acute Hemodynamic Stress in Patients With Chronic 
Heart Failure. Journal of the American College of Cardiology. 2009;54(18):1706-12. 
38. Yilmaz M, Erdem A, Yalta K, Turgut O, Yilmaz A, Tandogan I. Impact of beta-blockers 
on sleep in patients with mild hypertension: a randomized trial between nebivolol and 
metoprolol. Adv Therapy. 2008;25(9):871-83. 
39. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The 
European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life 
instrument for use in international clinical trials in oncology. Journal of the National Cancer 
Institute. 1993;85(5):365-76. 
22 
 
40. Yohannes AM, Dodd M, Morris J, Webb K. Reliability and validity of a single item 
measure of quality of life scale for adult patients with cystic fibrosis. Health and Quality of Life 
Outcomes. 2011;9(1):1-8. 
41. Cappelleri JC, Bushmakin AG, McDermott AM, Sadosky AB, Petrie CD, Martin S. 
Psychometric properties of a single-item scale to assess sleep quality among individuals with 
fibromyalgia. Health Qual Life Outcomes. 2009;7:54. 
42. Riegel B, Hanlon AL, Zhang X, Fleck D, Sayers SL, Goldberg LR, et al. What is the best 
measure of daytime sleepiness in adults with heart failure? Journal of the American Association 
of Nurse Practitioners. 2013;25(5):272-9. 
 
23 
 
Table 1. Socio-demographic and clinical characteristics for the total sample of adults with Pulmonary Arterial Hypertension and 
separated by sleep disturbance category 
Variable (N=191) Total  
N=191 
No Sleep 
Disturbance 
n=65 
Mild Sleep 
Disturbance  
(score 1-3) n=54 
Moderate Sleep 
Disturbance 
(score 4-7) n=41 
Severe Sleep 
Disturbance 
(8-10) n=31 
p-value 
Age (years) Mean + SD  53.2 +  15.1 53.2 + 16.4 54.5 + 15.2 52.7 +  51.2 51.6 +  13.5 .853 
Gender: female 162 (85%) 54 (83%) 48 (89%) 32 (78%) 28 (90%) .386 
Ethnicity: Caucasian 168 (88%) 56 (86%)  51 (94%) 35 (85%) 26 (84%) .357 
Marital Status: Married  97 (51%) 26 (43%) 30 (56%) 24 (59%) 17 (55%) .474 
Living with family/friends 141 (74%) 18 (30%) 40 (74%) 35 (85%) 23 (74%) .161 
College graduate  113 (59%) 39 (61%) 36 (67%) 23 (56%) 15 (48%) .641 
Working Status 
     Full-time  
     Part-time  
     Retired  
     Disabled  
 
36 (19%) 
21 (11%) 
43 (23%) 
77 (43%) 
 
13 (22%) 
5 (8%) 
18 (31%) 
23 (39%) 
 
9 (17%) 
16 (30%) 
15 (28%) 
21 (39%) 
 
10 (24%) 
6 (15%) 
6 (15%)  
15 (28%) 
 
4 (13%) 
4 (13%) 
4 (13%) 
18 (58%) 
 
.371 
PAH etiology 
     Idiopathic 
     Autoimmune 
 
114 (60%) 
36 (19%) 
 
36 (55%) 
10 (15%) 
 
32 (59%) 
12 (22%) 
 
27 (66%) 
5 (12%) 
 
19 (61%) 
9 (29%) 
 
24 
 
     Congenital heart disease 
     Other 
  
14 (7%) 
27 (14%) 
6 (9%) 
13 (20%) 
3 (6%) 
7 (13%) 
2 (5%) 
7 (17%) 
3 (10%) 
0 (0%) 
WHO Functional Class 
     I 
     II  
     III  
     IV  
 
22 (12%) 
36 (19%) 
54 (28%) 
79 (41%) 
 
 
13 (20%) 
17 (26%) 
17 (26%) 
18 (28%) 
 
7 (13%) 
9 (17%) 
12 (22%) 
26 (48%) 
 
2 (5%) 
7 (17%) 
16 (39%) 
16 (30%) 
 
0 
3 (10%) 
9 (29%) 
19 (61%) 
. 
.010 
Oxygen Use 115 (60%) 29 (49%) 37 (73%) 25 (69%) 24 (77%) .011 
Medications 
     CCB 
     ERA 
     PDE-5  
     Prostanoids  
     Diuretics  
     Digoxin  
     Beta Blockers 
 
46 (24%) 
95 (50%) 
110 (58%) 
75 (39%) 
117 (61%) 
29 (15%) 
25 (13%) 
 
14 (24%) 
37 (62%) 
36 (60%) 
29 (49%) 
40 (67%)  
8 (13%) 
10 (15%) 
 
14 (30%) 
25 (52%) 
34 (71%) 
20 (42%) 
31 (65%) 
9 (19%) 
6 (11%)  
 
11 (30%) 
21 (57%) 
25 (68%) 
15 (41%) 
23 (62%) 
6 (16%) 
6 (15%) 
 
7 (24%) 
12 (41%) 
15 (52%) 
11 (38%) 
23 (79%) 
6 (21%) 
3 (10%) 
 
.858 
.328 
.332 
.771 
.473 
.808 
.828 
25 
 
     ACEI/ARB 23 (12%) 12 (18%) 7 (13%) 4 (10%) 0 (0%) .071 
WHO= World Health Organization; CCB=Calcium channel blockers; ERA= Endothelin receptor antagonists; PDE-5= 
Phosphodiesterase 5-inhibitors; ACEI= angiotensin-converting enzyme inhibitors; ARB= angiotensin receptor blocker 
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Figure 1. Pulmonary Arterial Hypertension total number of symptoms by sleep disturbance groups 
 
a
=Post hoc pairwise difference p<.05 between no and mild sleep disturbance 
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b
= Post hoc pairwise difference p<.05 between no and moderate sleep disturbance 
c
= Post hoc pairwise difference p<.05 between no and severe sleep disturbance 
d
= Post hoc pairwise difference p<.05 between mild and severe sleep disturbance 
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Table 2 Pulmonary Arterial Hypertension symptom intensity (mean + SD) for the full sample and by sleep disturbance groups 
Symptom Intensity 
Mean+SD 
Total sample  
 
N=191 
No Sleep 
Disturbance 
n=65 
 
Mild Sleep 
Disturbance 
(score 1-3) n=54 
Moderate Sleep 
Disturbance 
(score 4-7) n=41 
Severe Sleep 
Disturbance 
(score 8-10) n=31 
p-value 
SOB with exertion
b,c,e,f 
6.2 + 2.7 5.1 + 2.8 6.1 + 2.7 6.7 +  2.3 8.1  + 2.0 <.001 
Fatigue
a,b,c,e,f 
5.0 + 2.5 3.5 + 2.4 5.0 +  2.5 5.8 +  1.9 6.9 +  1.7 <.001 
Swelling of 
ankles/feet
b,c.d,e 
2.9 + 3.1 1.6 + 2.5 2.4 +  2.8 4.1 +  3.0 5.0 +  3.1 <.001 
Palpitations
c,e 
2.9 + 2.6 2.1 + 2.2 2.7 + 2.3 3.0 + 2.4 4.7 + 3.3 <.001 
Raynaud’s phenomenonc,e 2.7 + 3.4 1.5 + 2.6 2.5 +  3.1 3.0 +  3.7 5.3 +  3.7 <.001 
Dizziness
b,c,e 
2.6 +  2.5 1.6 + 2.0 2.2 +  2.2 3.2 +  2.4 5.0 +  2.6 <.001 
Abdominal swelling
b,c,e 
2.3 + 3.2 1.0 + 2.2 1.9 + 3.0 3.5 + 3.6 4.1 + 3.6 <.001 
Cough
c,e 
2.3 + 2.6 1.7 + 2.1 1.9 + 2.2 2.8 + 2.7 3.7 + 3.3 .001 
Chest pain/discomfort
b,c,e 
2.2 + 2.4 1.3 + 1.7 2.0 + 2.1 2.6 + 2.3 3.8 + 3.1 <.001 
Loss of appetite
b,c,e 
1.9 + 2.5 1.0 + 1.9 1.3 + 1.7 2.4 + 2.3 4.1 + 3.4 <.001 
SOB at rest
c.e,f 
1.8 + 2.3 1.3 + 1.9 1.5 + 1.8 1.6 + 1.8 3.6 + 3.2 <.001 
SOB lying down
c 
1.7 + 2.2 0.7 +  0.9 1.6 + 2.0 1.9 + 2.3 3.2 + 3.0 <.001 
Nausea
c,e 
1.5 + 2.4 0.7 + 1.6 1.2 + 1.8 1.7 + 2.5 3.2 + 3.5 <.001 
Hoarseness
c,e 
1.5 + 2.3 1.1 + 2.1 1.0 + 1.6 1.7 + 2.5 3.1 + 2.9 <.001 
Awaken at night SOB
a,b,c,e 
0.9 + 1,8 0.1 + 0.4 0.7 + 1.4 1.1 + 2.0 2.5 + 2.8 <.001 
Syncope 0.5  + 1.5 0.4 + 1.6 0.3 + 1.1 0.3 + 1.1 1.1 +  2.3 .079 
Symptoms rated on 0-10 scale; 0 represents absence of the symptom; 10 represents worse possible symptom intensity. SOB=shortness 
of breath; Raynaud’s phenomenon= numb, painful hands or feet with cold and stress; p<.05 after correction for significant results for 
multiple comparisons: 
a
=Post hoc pairwise difference p<.05 between no and mild sleep disturbance 
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b
= Post hoc pairwise difference p<.05 between no and moderate sleep disturbance 
c
= Post hoc pairwise difference p<.05 between no and severe sleep disturbance 
d
= Post hoc pairwise difference p<.05 between mild and moderate sleep disturbance 
e
= Post hoc pairwise difference p<.05 between mild and severe sleep disturbance 
f
= Post hoc pairwise difference p<.05 between moderate and severe sleep disturbance 
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Table 3 Mood states in Pulmonary Arterial Hypertension (mean + SD) for the full sample and by sleep disturbance groups 
POMS 
 
Total sample  
 
N=191 
No Sleep 
Disturbance 
n=65 
 
Mild Sleep 
Disturbance 
(score 1-3) 
n=54 
Moderate Sleep 
Disturbance 
(score 4-7) 
n=41 
Severe Sleep 
Disturbance 
(score 8-10) 
n=31 
p-value 
Anxiety
b,c 
4.2 + 4.3 2.4 + 2.8
 
4.1 + 4.0 5.4 + 5.1 6.4 + 5.0 <.001 
Depression
b,c 
3.6 + 4.1 2.0+ 2.6
 
3.8 + 4.3 4.3 + 3.8 5.9 + 5.6 <.001 
Anger
b,c 
3.0 + 3.4 1.9 + 2.2
 
3.3 +3.6 3.7 + 3.6 4.2 + 4.1 .003 
Vigor
a,b,c 
6.4 + 4.5 8.9 + 4.4 6.1 + 4.0 4.5 + 3.9 4.5 + 3.8 <.001 
Fatigue
b,c,e,f 
 
8.7 + 5.3 6.0 + 4.5 8.1 + 4.5  10.2 + 4.2 13.8 + 5.1 <.001 
Confusion
b 
4.7 + 3.2 3.6 + 2.4
 
4.8 + 3.0 5.2 + 2.8 6.0 + 4.7 .003 
Total
a,b,c,e 
17.5 + 18.8 7.0 + 12.8
 
16.9 + 16.5 24.2 + 16.7 31.8 + 22.6 <.001 
POMS=Profile of Mood States; Higher scores indicate worse mood scores, except higher vigor represents increased vigor. Total 
scores range from -20-100, each subscale score ranges from 0-20.; p<.05 after correction for significant results for multiple 
comparisons: 
a
=Post hoc pairwise difference p<.05 between no and mild sleep disturbance 
b
= Post hoc pairwise difference p<.05 between no and moderate sleep disturbance 
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c
= Post hoc pairwise difference p<.05 between no and severe sleep disturbance 
d
= Post hoc pairwise difference p<.05 between mild and moderate sleep disturbance 
e
= Post hoc pairwise difference p<.05 between mild and severe sleep disturbance 
f
= Post hoc pairwise difference p<.05 between moderate and severe sleep disturbance 
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Table 4. Health Status in Pulmonary Arterial Hypertension (mean + SD) for the full sample and by sleep groups 
SF-36  
Subscale Scores 
Total sample  
N=191 
No Sleep 
Disturbance       
n=65 
 
Mild Sleep 
Disturbance 
(score 1-3)  n=54 
Moderate Sleep 
Disturbance 
(score 4-7)  
n=41 
Severe Sleep 
Disturbance 
(score 8-10) 
n=31 
p-value 
     General Health
a,b,c 
37.1 + 21.2 46.1 + 22.8
 
35.9 + 17.5 31.8 + 19.1 27.3 + 20.2 <.001 
     Physical function
a,b,c 
41.5 + 25.9 52.6 + 27.6 35.7 + 22.8 40.1 + 24.5 30.3 + 20.9 <.001 
     Role physical
a,b,c 
36.4 + 40.3 56.5 + 41.8 34.7 + 38.4   22.8 + 34.0 15.3 + 28.6 <.001 
     Pain
a,b,c,e 
66.3 + 27.5 82.1 + 21.7 63.7 + 24.4 61.1 + 26.0 45.2 + 28.2 <.001 
     Vitality
b,c,e 
41.3 + 22.7 51.3 + 22.6 42.0 + 22.7 34.6 + 18.7 27.7 + 18.2 <.001 
     Social function
a,b,c 
65.5 + 26.4 78.7 + 20.3
 
63.6 + 24.9 54.3 + 28.2 56.0 + 27.1 <.001 
     Mental health
a,b,c 
71.9 + 19.3 80.9 + 13.2 70.3 + 20.2 65.0 + 20.2 65.1 + 20.5 <.001 
     Role emotional
a,c 
67.0 + 41.5 81.5 + 33.3
 
57.9 + 42.1 65.1 + 44.7 54.8 + 44.4 .003 
Composite Summary 
scores 
      
     Mental health
a,b,c 
61.5 + 21.0 73.1 + 15.3
 
58.6 + 21.0 54.8 + 20.0 50.9 + 22.4 <.001 
     Physical health
a,b,c,e 
45.4 + 22.7 59.4 + 22.2 42.4 + 18.2 39.0 + 19.8 29.6 + 18.4 <.001 
Higher scores indicate better health; score range 0-100; p<.05 after correction for significant results for multiple comparisons: 
a
=Post hoc pairwise difference p<.05 between no and mild sleep disturbance 
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b
= Post hoc pairwise difference p<.05 between no and moderate sleep disturbance 
c
= Post hoc pairwise difference p<.05 between no and severe sleep disturbance 
d
= Post hoc pairwise difference p<.05 between mild and moderate sleep disturbance 
e
= Post hoc pairwise difference p<.05 between mild and severe sleep disturbance 
f
= Post hoc pairwise difference p<.05 between moderate and severe sleep disturbance 
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